Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Recruiting 5 Unknown 3 Active not recruiting 3 Not yet recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4 Gastrointestinal 4 Thoracic 3 Breast 3 Sarcoma 2 Gynecologic 2 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Endocrine 1

Conditions

Leukemia, B-Cell 1

Interventions

Rituximab 227 Cyclophosphamide 142 fludarabine 69 Vincristine 66 Methotrexate 62 Doxorubicin 54 fludarabine phosphate 53 Lenalidomide 49 Etoposide 49 Cytarabine 48 Prednisone 47 Dexamethasone 44 Filgrastim 43 Bortezomib 38 Whole-Body Irradiation 34 Gemcitabine 34 Melphalan 32 Radiotherapy 30 ibrutinib 29 Granulocyte Colony-Stimulating Factor 29 Alemtuzumab 29 obinutuzumab 28 Tacrolimus 28 Mycophenolic Acid 28 Antilymphocyte Serum 28 venetoclax 27 Calcium Dobesilate 27 Busulfan 27 Bendamustine Hydrochloride 27 idelalisib 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Observation × Lymphoid × Clear all

NCT01039376 2019-07-30

PROLONG

Novartis

Phase 3 Terminated

480 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡